Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal formation of PCP-treated mice

Shuji Iritani, Hirotaka Sekiguchi, Chikako Habuchi, Youta Torii, Shinnosuke Yamada, Yukari Waki, Yukihiro Noda, Hiroshi Furukawa, Toshitaka Nabeshima, Norio Ozaki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The exact pathophysiology of schizophrenia is unknown despite intensive scientific studies using molecular biology, psychopharmacology, neuropathology, etc. It is thought that neurodevelopmental failures such as neuronal network incompetence and the inappropriate formation of neurons affect the neurotransmitters. Several animal models have been created to investigate the etiology of this disease. In this study, we investigated the expression of vesicle monoamine transporter 2 (VMAT2), which has a significant role in neurotransmission, in the hippocampal formation in 1-phenylcyclohexylpiperazine (PCP)-treated mice using immunohistochemical staining technique to clarify neuronal abnormalities. PCP-treated mice are thought to be one of novel animal models for schizophrenia. The expression of VMAT2 in the hippocampal formation was significantly reduced overall in the PCP-treated mice compared to that in control (saline-treated) mice, also these reductions were observed throughout the brain. These facts implied that the pathophysiology of this disease involves abnormal monoaminergic transmission through VMAT2, despite PCP was the N-methyl-d-aspartate (NMDA) receptor antagonist that might induce glutamatergic abnormality. Since insufficient or excess release of neurotransmitter might alter neurochemical function and neurotransmission, VMAT2 might be an important target for biological research in psychiatric disease including schizophrenia.

Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalNeuroscience Research
Volume68
Issue number2
DOIs
Publication statusPublished - 01-10-2010
Externally publishedYes

Fingerprint

Hippocampus
Schizophrenia
Synaptic Transmission
Neurotransmitter Agents
Animal Models
Psychopharmacology
Psychiatry
Molecular Biology
Staining and Labeling
Neurons
Brain
Research

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)

Cite this

Iritani, S., Sekiguchi, H., Habuchi, C., Torii, Y., Yamada, S., Waki, Y., ... Ozaki, N. (2010). Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal formation of PCP-treated mice. Neuroscience Research, 68(2), 125-130. https://doi.org/10.1016/j.neures.2010.06.005
Iritani, Shuji ; Sekiguchi, Hirotaka ; Habuchi, Chikako ; Torii, Youta ; Yamada, Shinnosuke ; Waki, Yukari ; Noda, Yukihiro ; Furukawa, Hiroshi ; Nabeshima, Toshitaka ; Ozaki, Norio. / Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal formation of PCP-treated mice. In: Neuroscience Research. 2010 ; Vol. 68, No. 2. pp. 125-130.
@article{e2371cce306b45419b802d39adb0ed25,
title = "Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal formation of PCP-treated mice",
abstract = "The exact pathophysiology of schizophrenia is unknown despite intensive scientific studies using molecular biology, psychopharmacology, neuropathology, etc. It is thought that neurodevelopmental failures such as neuronal network incompetence and the inappropriate formation of neurons affect the neurotransmitters. Several animal models have been created to investigate the etiology of this disease. In this study, we investigated the expression of vesicle monoamine transporter 2 (VMAT2), which has a significant role in neurotransmission, in the hippocampal formation in 1-phenylcyclohexylpiperazine (PCP)-treated mice using immunohistochemical staining technique to clarify neuronal abnormalities. PCP-treated mice are thought to be one of novel animal models for schizophrenia. The expression of VMAT2 in the hippocampal formation was significantly reduced overall in the PCP-treated mice compared to that in control (saline-treated) mice, also these reductions were observed throughout the brain. These facts implied that the pathophysiology of this disease involves abnormal monoaminergic transmission through VMAT2, despite PCP was the N-methyl-d-aspartate (NMDA) receptor antagonist that might induce glutamatergic abnormality. Since insufficient or excess release of neurotransmitter might alter neurochemical function and neurotransmission, VMAT2 might be an important target for biological research in psychiatric disease including schizophrenia.",
author = "Shuji Iritani and Hirotaka Sekiguchi and Chikako Habuchi and Youta Torii and Shinnosuke Yamada and Yukari Waki and Yukihiro Noda and Hiroshi Furukawa and Toshitaka Nabeshima and Norio Ozaki",
year = "2010",
month = "10",
day = "1",
doi = "10.1016/j.neures.2010.06.005",
language = "English",
volume = "68",
pages = "125--130",
journal = "Neuroscience Research",
issn = "0168-0102",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Iritani, S, Sekiguchi, H, Habuchi, C, Torii, Y, Yamada, S, Waki, Y, Noda, Y, Furukawa, H, Nabeshima, T & Ozaki, N 2010, 'Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal formation of PCP-treated mice', Neuroscience Research, vol. 68, no. 2, pp. 125-130. https://doi.org/10.1016/j.neures.2010.06.005

Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal formation of PCP-treated mice. / Iritani, Shuji; Sekiguchi, Hirotaka; Habuchi, Chikako; Torii, Youta; Yamada, Shinnosuke; Waki, Yukari; Noda, Yukihiro; Furukawa, Hiroshi; Nabeshima, Toshitaka; Ozaki, Norio.

In: Neuroscience Research, Vol. 68, No. 2, 01.10.2010, p. 125-130.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immunohistochemical study of vesicle monoamine transporter 2 in the hippocampal formation of PCP-treated mice

AU - Iritani, Shuji

AU - Sekiguchi, Hirotaka

AU - Habuchi, Chikako

AU - Torii, Youta

AU - Yamada, Shinnosuke

AU - Waki, Yukari

AU - Noda, Yukihiro

AU - Furukawa, Hiroshi

AU - Nabeshima, Toshitaka

AU - Ozaki, Norio

PY - 2010/10/1

Y1 - 2010/10/1

N2 - The exact pathophysiology of schizophrenia is unknown despite intensive scientific studies using molecular biology, psychopharmacology, neuropathology, etc. It is thought that neurodevelopmental failures such as neuronal network incompetence and the inappropriate formation of neurons affect the neurotransmitters. Several animal models have been created to investigate the etiology of this disease. In this study, we investigated the expression of vesicle monoamine transporter 2 (VMAT2), which has a significant role in neurotransmission, in the hippocampal formation in 1-phenylcyclohexylpiperazine (PCP)-treated mice using immunohistochemical staining technique to clarify neuronal abnormalities. PCP-treated mice are thought to be one of novel animal models for schizophrenia. The expression of VMAT2 in the hippocampal formation was significantly reduced overall in the PCP-treated mice compared to that in control (saline-treated) mice, also these reductions were observed throughout the brain. These facts implied that the pathophysiology of this disease involves abnormal monoaminergic transmission through VMAT2, despite PCP was the N-methyl-d-aspartate (NMDA) receptor antagonist that might induce glutamatergic abnormality. Since insufficient or excess release of neurotransmitter might alter neurochemical function and neurotransmission, VMAT2 might be an important target for biological research in psychiatric disease including schizophrenia.

AB - The exact pathophysiology of schizophrenia is unknown despite intensive scientific studies using molecular biology, psychopharmacology, neuropathology, etc. It is thought that neurodevelopmental failures such as neuronal network incompetence and the inappropriate formation of neurons affect the neurotransmitters. Several animal models have been created to investigate the etiology of this disease. In this study, we investigated the expression of vesicle monoamine transporter 2 (VMAT2), which has a significant role in neurotransmission, in the hippocampal formation in 1-phenylcyclohexylpiperazine (PCP)-treated mice using immunohistochemical staining technique to clarify neuronal abnormalities. PCP-treated mice are thought to be one of novel animal models for schizophrenia. The expression of VMAT2 in the hippocampal formation was significantly reduced overall in the PCP-treated mice compared to that in control (saline-treated) mice, also these reductions were observed throughout the brain. These facts implied that the pathophysiology of this disease involves abnormal monoaminergic transmission through VMAT2, despite PCP was the N-methyl-d-aspartate (NMDA) receptor antagonist that might induce glutamatergic abnormality. Since insufficient or excess release of neurotransmitter might alter neurochemical function and neurotransmission, VMAT2 might be an important target for biological research in psychiatric disease including schizophrenia.

UR - http://www.scopus.com/inward/record.url?scp=77956284074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956284074&partnerID=8YFLogxK

U2 - 10.1016/j.neures.2010.06.005

DO - 10.1016/j.neures.2010.06.005

M3 - Article

VL - 68

SP - 125

EP - 130

JO - Neuroscience Research

JF - Neuroscience Research

SN - 0168-0102

IS - 2

ER -